Attention Business/Financial Editors:

Update on Neptune Technologies Notes

LAVAL, QC, Nov. 27 /CNW Telbec/ - Neptune Technologies & Bioressources
Inc. ("Neptune") (NASDQ.NEPT-TSX.V.NTB) and Acasti Pharma Inc. ("Acasti
Pharma"), a pharmaceutical subsidiary of Neptune, announce that Neptune has
assigned to Acasti Pharma all its obligations relating to the notes held by
holders who have not accepted the Exchange into Acasti Pharma units, as
described in Neptune's and Acasti Pharma's press release dated October 21,
2008 (the "Assigned Notes").
Following this assignment, Acasti Pharma has decided, as permitted under
the terms of the notes, to proceed with the pre-payment of the Assigned Notes.
Acasti Pharma will effect this pre-payment by the issuance of units, each
unit being issued at a deemed price of $0.001 and being comprised of one Class
A share of Acasti Pharma and one warrant to purchase one Class A share of
Acasti Pharma, exercisable at a price of $0.40 and expiring in two years
(which is the same consideration that the note holders having accepted the
Exchange received) to all holders that qualify to receive such securities
according to their applicable regulations, whereas the payment will be made in
cash to the holders not qualified to receive such securities according to
their applicable regulations. 98.5% of Neptune notes holder will have been
paid in Acasti Pharma units.
Acasti Pharma constitutes a public non-listed company controlled by
Neptune and its financial information will be publicly disclosed. Acasti
Pharma's first quarterly report will be released within sixty (60) days
following the end of the quarter ending November 30, 2008 conform to
regulatory requirements. There is presently no market for the shares or
warrants of Acasti Pharma.
Neptune Technologies also announces that it decided not to renew its
contract with its investor relation firm for the U.S. market Integrated
Corporate Relations Inc. ("ICR") and to terminate it before term effective
November 24, 2008.

About Acasti Pharma

Acasti Pharma, a subsidiary of Neptune Technologies, is developing a
product portfolio of proprietary novel long-chain omega-3 phospholipids for
chronic cardiovascular conditions. Phospholipids are the major component of
cell membranes and are essential for all vital cell processes. They are one of
the principal constituents of High Density Lipoprotein (good cholesterol) and
play, as such, an important role in modulating cholesterol efflux. Acasti
Pharma's proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have
substantial health benefits and which are stabilized by potent antioxidants.

About Neptune Technologies

Neptune researches and develops proprietary bioactive ingredients and
products for nutraceutical and pharmaceutical applications and is carrying out
clinical research to show the therapeutic benefits in various medical
indications. The Company continuously expands its intellectual property
portfolio and has obtained many regulatory approvals allowing
commercialization of its products in various geographic markets. Neptune
continues to strongly support its strategic development plan to form
partnership with worldwide leaders in the nutraceutical industries. Neptune
signed agreements with Nestlé and Yoplait, worldwide leading food
manufacturers, and expects to launch its first functional food product in
early 2009 with its partners Marine Life Science and Weider Global Nutrition.

Neither NASDAQ nor TSX venture exchange accepts responsibility for the
adequacy or accuracy of this press release.

Statements in this press release that are not statements of historical or
current fact constitute "forward-looking statements" within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities
laws. Such forward-looking statements involve known and unknown risks,
uncertainties, and other unknown factors that could cause the actual results
of the Company to be materially different from historical results or from any
future results expressed or implied by such forward-looking statements. In
addition to statements which explicitly describe such risks and uncertainties,
readers are urged to consider statements labelled with the terms "believes,"
"belief," "expects," "intends," "anticipates," "will," or "plans" to be
uncertain and forward-looking. The forward-looking statements contained herein
are also subject generally to other risks and uncertainties that are described
from time to time in the Company's reports filed with the Securities and
Exchange Commission and the Canadian securities commissions.

For further information: Neptune Technologies and Acasti Pharma Contact:
Toni Rinow, Ph.D., MBA, Corporate Development & Investor Relations, Neptune
Technologies & Bioressources Inc., (450) 687-2262, [email protected],
www.neptunebiotech.com

http://www.newswire.ca/en/releases/a...